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The coronavirus (COVID-19) pandemic due to SARS-CoV-2 has taken-hold all over the 
world. Our Chinese colleagues, who were on the pandemic frontline, are now starting to describe 
the clinical features and cardiovascular presentations seen in these patients and particularly the 
signals provided by biomarkers (1-4).  In this issue of the journal, the group from Wuhan 
Renmin University describe, in one of the larger cohorts (n = 671) reported to date, the 
importance of increases in cardiac troponin I (cTnI) in patients with a COVID-19 infection who 
were sick enough to require respiratory support (1). The authors found that a cTnI value of 
>0.026ng/mL (AUC 0.92) was the optimal threshold for predicting in-hospital mortality, which 
is within the normal population range for this assay (<0.04ng/mL). Overall, 62 (9.2%) patients 
died in hospital, of whom 53 (85% of deaths) had a cTnI >0.026ng/mL and 47 (76%) had values 
>0.04ng/mL. Mortality was 50% (53 of 106) for patients with a cTnI >0.026 ng/ml compared to 
just nine deaths (1.6%) amongst 565 patients with a lower cTnI.  In multivariable analysis, older 
age and cardiovascular comorbidities were associated with higher cTnI.  ese findings are 
consistent with prior reports (1-4).    
There are some issues about how cTnI values were used in this analysis that should be 
appreciated.  Only single samples, mostly obtained on admission, were used. Many more patients 
would have had an elevated cTnI at some point during their hospitalization.   Multiple sampling 
to identify changes in values, reflecting progression or resolution of disease, will probably add to 
the prognostic significance of cTnI (6).   The hospital used the Siemens Ultra assay, a non-high 
sensitivity assays.  It is very likely that when high sensitivity troponin (hscTn) assays are used, 
the proportion with increased values will be even greater.   The optimal value for prognostic 
classification was reported to be 0.026 ng/ml which is within the normal range (<0.04 ng/ml) for 
this assay.  Had an hscTn assay been used, this confusing overlap might have been avoided.  
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Clinicians should also appreciate that, in general, cTnT is more likely to be elevated for reasons 
other than ischaemia when compared to cTnI (7) and that hscTnT may predict outcome more 
strongly in these circumstances (8).  The reasons for this are unclear but clinicians reading these 
articles need to consider this issue in extrapolating these data to their local practice.  These 
factors in aggregate have probably led to underestimation of the frequency of and magnitude of 
cTn increases based on the methods used in this manuscript.     
There are many reasons why troponin elevations might occur during a COVID infection 
(figure 1) although this was not the focus of the current manuscript.  Patients with cardiovascular 
diseases (CVD) and risk factors such as hypertension and diabetes are at high risk of developing 
severe manifestations of COVID-19. Whether this reflects a greater susceptibility to, or more 
severe consequences of infection is currently unclear. There is much speculation over the role of 
the ACE-2 receptor for CoV-2 cellular docking which may be influenced by CVD and/or its 
treatment (9). Increases in cTn are common in patients with chronic stable CVD, especially when 
complicated by heart failure, and portend a worse prognosis (10).   Modest elevations in cTn 
during COVID infections may just be a surrogate marker for the underlying severity of pre-
existing CVD.  
Increases in cTn may also reflect acute myocardial injury.  In some cases, this will be due 
to acute atherosclerotic plaque disruption, coronary thrombosis and epicardial coronary 
occlusion (a so called type 1 event).   However, in critically ill patients, supply-demand 
imbalance leading to myocardial injury is more common (11), due to the metabolic stress of the 
infection because of tachycardia, hypoxia, acidosis and hypotension with or without substantial 
pre-existing epicardial coronary disease.  When this is accompanied by clinical evidence of 
myocardial ischaemia it is termed Type-2 myocardial infarction. When myocardial ischaemia is 
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not present, the proper term for the increased cTn even with a rising pattern is “acute myocardial 
injury” per the Universal Definition of Myocardial Infarction (12). 
In data published a decade ago, long before we knew about COVID, increases in non-
hscTn were found to be common (42%) in patients severe respiratory infections and predicted a 
higher mortality (5).  Increases in cTn are unsurprising in patients who are close to death but, 
importantly, increases in cTn improved prediction of outcome for those in the grey-zone of 
intermediate risk. Thus, the patients for whom cTn provided unique information was not the 
group with very high APACHE or SOFA scores but those with lower scores where an elevated 
troponin told the physician that the risk was greater than the clinical picture suggested.  Indeed, 
in the present study, cTnI appeared to be of little prognostic value in older people who were 
uniformly at high-risk.  It’s value was in younger patients with markedly elevated cTn values 
(Figure 5B – right hand panel in reference 1). Patients with severe respiratory disease and an 
elevated cTnI generally require treatment of the underlying lung injury rather than an invasive 
coronary intervention (13).  This is a difficult issue for some cardiologists, who believe that 
whenever troponin is elevated, angiography is obligatory.  The COVID-19 pandemic provides a 
unique opportunity to change that sort of thinking.  
This issue may be vexing to cardiologists because of the well reported temporal 
relationship between antecedent viral infections of the respiratory tract and the subsequent 
development of myocardial infarction (14).  However at present, it appears that type-1 
myocardial infarction is not common in this COVID-19 pandemic (1-4).  Perhaps patients are 
choosing not to come to hospital for medical advice? Perhaps social-distancing is reducing the 
risk of events?  However, the inflammatory response may not be benign.  Infection with SARS-
CoV-2 impairs endothelial function and haemostatic balance, thus increasing thrombin activity, 
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reducing plasminogen activator inhibitor-1 (PAI-1) activity, and accelerating production of fibrin 
degradation products and D-Dimer (15).   Endothelial inflammation, vascular oedema and 
disseminated intravascular coagulation may lead to micro-vascular dysfunction and occlusion 
(15).  These factors may exacerbate myocardial oxygen supply/demand imbalance due to 
hypoxia and tachycardia.  Such an effect would be synergistic with the presence of fixed 
coronary stenoses, pulmonary hypertension due to lung injury, hypoxia and pulmonary embolism 
as well.  They could at least in theory lead to coronary thrombosis as well.   These findings are 
very similar to those reported previously with acute respiratory distress syndrome (16).   In 
addition, with systemic infection, inflammation in many organs is expected.  
Whether, the severe inflammatory response driven by a cytokine storm in COVID 
destabilizes coronary plaques leading to rupture and intracoronary thrombus formation remains 
speculative.  Recently, there have been newspaper reports of sudden cardiac death.  Many of 
these may have been due to pulmonary emboli which are said to be common (17).   They could 
also be due primarily to an arrhythmia or less likely some could be due to acute coronary 
occlusion.  Although arrhythmias have been described in the present and other studies of 
COVID-19, it is not clear that, absent drugs that prolong the QTc interval which some now use 
as therapy that the incidence of these are greater than one might expect from patients with any 
severe respiratory infection leading to myocardial injury (5,18). 
There are other potential causes of acute myocardial injury.  Widespread inflammation 
and cell death likely accounts for the dramatic increases in serum ferritin observed in severe 
COVID-19. The increase in cTn may often reflect the heart’s ‘share’ of the generalized 
inflammation rather than organ-specific myocarditis.  In addition, although only documented in 
case reports, other diseases seen in the critically-ill can also occur such as Takotsubo 
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cardiomyopathy (19).  Case-reports also provide anecdotal evidence of myocarditis in patients 
with COVID-19 (20).  However, there are no robust published data on the prevalence and 
severity of concomitant myocarditis using sophisticated imaging or detailed pathological 
analyses.  Based on present information, the incidence of myocarditis may not be high.  The 
cases that do occur are reminiscent of the cases of acute myocarditis mimicking myocardial 
infarction reported many years ago (21). Pulmonary hypertension, either due to lung injury and 
hypoxia or due to pulmonary embolism and thrombosis, may place a severe load on the right 
ventricle leading to myocardial damage and troponin release and the high frequency of venous 
thromboembolism recently described (17).    
    In conclusion, serial measurements of troponin might be useful in predicting risk 
in patients who are not already severely ill.  Whether small increases in troponin reflect 
disproportionate myocardial involvement in the systemic inflammatory response to infection, 
COVID-19 or other organisms, is uncertain.   Many of the increases in cTn observed likely 
reflect myocardial injury due to preexisting disease and/or in response to critical illness.    The 
inflammatory and coagulopathic stress responses may be nonspecific or more marked with 
Coronavirus. Organ-specific myocarditis may be uncommon. More research is required to 
determine whether acute myocardial injury is a marker or driver of clinical outcomes and 
whether it leaves a legacy of myocardial dysfunction, fibrosis, scar and arrhythmia. Our Chinese 
colleagues have made an essential first-step on this important path of research that will help us 
understand this new disease and improve patient-care.   
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Figure Legend 
Possible mechanisms for myocardial injury (an inceased cTn value) in patients with Covid-19.  
Based on present data, orange boxes denote common etiologies.  Yellow boxes denote 
uncommon causes and red boxes, situations that are common with Covid -19 disease and may 
have a role in causing cardiac injury in some patients.    
 
